BioSpace News Archive

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, announced today that it has been designated as a Preferred Analytics Vendor by the Association for Community Affiliated Plans (ACAP).

The Wyoming, Michigan-based healthcare organization will partner with Glytec to provide patients an integrated model of technology-enabled glycemic management

Grand River Aseptic Manufacturing, Inc., a leading parenteral contract development and manufacturing organization, has implemented its fully-automated serialization and aggregation processes for commercial injectable drug products.

Akebia Therapeutics, Inc. announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets.

Ocular Therapeutix, Inc announced that it has settled litigation with Mati Therapeutics, Inc., regarding alleged infringement of U.S. Patent 7,922,702.

Genomic Health, Inc. announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results.

RLDatix, a leading provider of solutions that drive patient safety, quality improvement and harm reduction in healthcare, announced today that Jeff Surges has been appointed as CEO, effective immediately.

Holon Solutions, healthcare’s leading data liberator, announced today it has been awarded U.S. Patent No. 15/796,400 for context-sensing technology that surfaces actionable patient data to providers within any electronic health record (EHR), and from any third-party source, without the need for interfaces.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on Tuesday, May 14, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss first quarter financial results.

Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced today the publication of data demonstrating the continued burden of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in preterm infants in the U.S.